To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
So, wouldn't it be nice to have a quantitative way to say how deep the remission is? Historically, it’s been felt that if you just scratch the surface and get below the 5 percent blast level, you’re probably going to relapse. And if you get deeper, you might not.
Jason M. Broderick
The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.
Kristie L. Kahl
A study, conducted at Penn State College of Medicine, demonstrated that patients with melanoma who received immunotherapy while also taking a specific type of beta blocker lived longer than those who received immunotherapy alone.


Barbara Tako
Breast cancer survivor shares how she approaches her ongoing chemo brain.
Kim Johnson
Knowing that my sister gained remission gives me an immense bias, but ask the question, “Good or bad?” now and my answer may just be, “hard to tell.”
Bonnie Annis
Many breast cancer survivors choose to adorn their chests with beautiful designs in an effort to camouflage unsightly scars. Could this practice be dangerous to their health? Read one survivor's viewpoint.

CURE Conections®

Philippa Cheetham, MD; Sara F. Martin, MD; and Evan C. Osmundson, MD, PhD, remark on recent improvements in managing advanced lung cancer, and offer insight regarding future therapies that show promise.
Philippa Cheetham, MD; Sara F. Martin, MD; Evan C. Osmundson, MD, PhD; and Leora Horn, MD, MSc, reflect on common challenges faced while treating advanced lung cancer and discuss their considerations for creating long-term treatment plans.
Philippa Cheetham, MD; Sara F. Martin, MD; and Leora Horn, MD, MSc, discuss how they counsel patients on strategies for managing side effects from newer therapies in advanced lung cancer.


Julie R. Libon
A myeloproliferative neoplasm survivor and advocate offers advice on how loved ones can support a patient with cancer.
Cristiana Sessa, M.D.
Cristiana Sessa, M.D., of the Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.
Susan Leclair, Ph.D., CLS (NCA)

Susan Leclair, Ph.D., CLS (NCA), retired lab professor at University of Massachusetts, Dartmouth, discusses how moderating an online forum for patients with myeloproliferative neoplasms (MPNs) has inspired her.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable